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Dynamic Research
Adult stem cells could
one day be used to treat
damaged tissue.

7

8

The Buzz
House Call explains t e
difference between embryonic and adult stem cells.
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DiaLog
Directed parathyroid
surgery is highly successful
and reduces morbidity.
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by Katie Prout Matias

ike detectives tracking
clues that a suspect
leaves behind, surgical
oncologists use a
technique called sentinel lymph
node biopsy to find cancer cells
that have escaped the tumor and
threaten to infiltrate other parts
of the body. The sentinel node,
or the first lymph node to which
extracellular fluid from a tumor
drains, acts as the gateway to the
lymphatic system and beyond.
Thus, the presence or absence of
tumor cells in the sentinel node
provides a wealth of information
about the nature of a cancer and
how best to treat it.

L

(Continued on next page)
To locate the sentinel lymph node in a
patient with breast cancer, Mary
Jennings (left), an advanced practice
nurse in the Department of Surgical
Oncology, and Dr. Kelly Hunt, an
associate professor in the department, watch
the digital readout from a gamma probe.
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Sentinel Lymph Node Biopsy
(Continued from page 1)
The current standard of care for
melanoma and breast cancer, sentinel
lymph node biopsy spares patients
who have no trace of disease in their
sentinel nodes from the sometimes severe
complications of having an entire nodal
basin removed: chronic swelling, discomfort, infection, and reduced mobility. The
procedure also allows for more thorough
pathologic analysis and more accurate
staging, perhaps even improving survival
rates in patients with certain cancers. As
researchers at The University of Texas
M. D. Anderson Cancer Center work to
maximize the benefits of sentinel lymph
node biopsy, however, two issues remain
unresolved: What is the best way to find
and manage micrometastatic disease, and
how important are alternative lymphatic
drainage patterns?

Finding the sentinel node
Surgical oncologists hunt for the
sentinel lymph node armed with a
radioactive tracer and blue dye. The
radioactive tracer is used first to illuminate the route of the tumor's drainage.
During lymphoscintigraphy, the tracer
is injected around the tumor or biopsy
site, and a gamma camera captures its
final destination.
In an operating room, the surgeons
use a hand-held gamma probe to find
the "hot spot" or area of high concentration of radiation. This is where the
sentinel node, packed full of radioactive
tracer, lies. They next inject the bright
blue dye around the tumor site and
massage it to encourage the dye to
migrate quickly to the sentinel node.
After a few minutes of massaging, the
surgeons cut a small opening in the
skin at the hot spot and look for one
or more bean-like nodules dyed bright
blue.
Once the surgeons have identified
any suspicious nodes, they remove them
and pass them on to the pathologist.
The presence and number of tumor cells
in the lymph nodes are strong prognostic factors. "The amount of disease
within that lymph node is a very good
predictor of the likelihood that a
patient will remain cancer free," said
Jeffrey Lee, M.D., a professor in the
Department of Surgical Oncology.
2
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"Patients with larger amounts of cancer
are more likely to suffer a relapse."

Identifying micrometastatic
disease
In the past, when completion
dissections were routinely performed
on all patients, pathologists would have
to scrutinize 15 to 30 lymph nodes, a
time-consuming and expensive task,
according to Ebrahim Delpassand, M.D.,
an associate professor in the Department of Nuclear Medicine. Now, they
usually inspect one or two sentinel
nodes, which allows them to more

meticulously examine each node
for micrometastases.
Finding pathology assays that
can quickly and accurately identify
micrometastasis is now the most
important goal for sentinel lymph node
biopsy because it is the key to managing
tumors, according to Merrick Ross,
M.D., a professor in the Department of
Surgical Oncology.
In the Sunbelt Melanoma Trial,
Ors. Lee and Ross are investigating the
use of polymerase chain reaction (PCR)
to detect cancer cells at the molecular
level. U sing PCR, which could be

Sentinel Lymph
Node Biopsy
Shows Promise
in Eye and
Colon Cancers
by Katie Prout Matias

A

s the use of sentinel
lymph node biopsy in
melanoma and breast
cancer continues to evolve ,
researchers at The University
of Texas M. D. Anderson
Cancer Center are finding
ways to modify and adapt the
procedure for other types of
cancer, including conjunctival,
eyelid, and colon cancers.
Performing sentinel lymph node
biopsy in tumors of the eye requires skill
and teamwork because of the unique
anatomic considerations in the periocular region. "It requires someone who is
familiar with the eye to work closely
with someone who is very familiar with
doing sentinel lymph node biopsy in the
head and neck region. Head and neck
sentinel node biopsy is a little different
from the rest of the body. It has a higher
learning curve," said Bita Esmaeli,
M.D., an associate professor and chief

of the Section of Ophthalmology in the
Department of Plastic Surgery at M. D.
Anderson and an ophthalmic plastic
surgeon. Dr. Esmaeli and Merrick Ross,
M.D., a professor in the Department of
Surgical Oncology at M. D. Anderson,
have adapted sentinel lymph node
biopsy for conjunctival and eyelid
tumors.
"The problem with the head and
neck region is that it is so rich in
lymphatics, and the ambiguity of
lymphatic drainage patterns is really
high," said Dr. Ross. "But in conjunctival melanomas, our experience has been
that the lymphatic drainage patterns are
actually relatively straightforward; they
almost always drain to the parotid
region and the upper neck."
Drs. Esmaeli and Ross have also
performed sentinel lymph node biopsies
for eyelid tumors, including sebaceous
cell carcinomas and Merkel cell carcinomas, which can have rates of nodal
involvement of 20% to 50%.
Initial concerns that performing a
sentinel lymph node biopsy in the eye
region might permanently discolor the
eye with the blue dye used to locate
the sentinel node or cause cataracts or
dryness from the radioactive tracer have
not materialized. Another issue with
the radioactive tracer was how much to
inject. Dr. Esmaeli noticed that, because
the conjunctiva is a mucous membrane
with a contiguous underlying space and
the eye is so small, injecting the usual
volume of tracer used for sentinel node
biopsy in other locations caused the

sensitive enough to detect one melanoma cell among a million normal cells,
they are looking in lymph nodes for the
presence of genes that are typically
expressed in melanoma. "We're hopeful
that some of these techniques may help
us to identify small amounts of cancer
that are not apparent looking under the
microscope with our best techniques,"
said Dr. Lee.
For patients with breast cancer,
researchers have not yet identified which
markers could be used with PCR.
Instead, they are focusing on ways to
intraoperatively examine lymph nodes

for micrometastases so that if a positive
node is discovered, the surgeons will not
have to operate a second time to remove
the rest of the nodes. Currently, in
examining the nodes of patients with
breast cancer, pathologists at M. D.
Anderson use touch preparations in
which they slice the node, pat the
two halves onto slides, and examine
the cells that stick to the slides.
The accurate staging made possible
by such painstaking pathology allows
oncologists to choose the most appropriate therapies. "I think it really helps us to
get a little bit closer to identifying the

removed from the surface
of his eye. Ultrasonography
and magnetic resonance
imaging found no disease
in his lymph nodes. In this
situation, the standard of
care is to wait and see if
the melanoma metastasizes,
which can occur in
as many as 30% of conjunctival melanomas.
Instead, the man's local
ophthalmologist referred
him to M. D. Anderson,
where Drs. Esmaeli and
Ross performed a sentinel
lymph node biopsy and
identified three sentinel
nodes. One turned out
to be histologically
positive for metastatic
melanoma, and the
patient's melanoma was
upgraded from stage I
Dr. Bita Esmaeli, an associate professor and chief of
to stage III.
the Section of Ophthalmology in the Department of Plastic
"Sentinel node biopsy
Surgery, uses a model eyeball to demonstrate to patients
drastically changed this
where she will inject the radioactive tracer and blue dye
patient's treatment; instead
during sentinel lymph node biopsy.
of just waiting for his
agent to spread on the surface of the eye metastatic disease to become clinically
obvious, we found his microscopic
and drain to nonspecific nodal basins.
By using a smaller needle and decreasing lymph node metastasis early, and he had
neck dissection, radiation therapy, and
the volume, she was able to identify the
was enrolled in a phase III trial for
sentinel node or nodes successfully.
systemic interferon," said Dr. Esmaeli.
To illustrate how the use of sentinel
"For aggressive malignancies of the
lymph node biopsy can affect the
treatment of eye tumors, Dr. Esmaeli
conjunctiva and eyelid, sentinel lymph
related the case of a 58-year-old man
node biopsy is an important advance
who had a conjunctival melanoma
because we would otherwise miss

patients at high risk for metastatic
disease so that we can be more careful
with our treatments," said Kelly Hunt,
M.D., an associate professor in the
Department of Surgical Oncology.
"Certainly, we help a lot of people with
chemotherapy, but there are some people
that we're not helping."

Too much of a good thing?
Using these highly sensitive techniques, pathologists are uncovering
more micrometastases than they have in
the past. "We found that the more you
(Continued on page 4)

microscopic nodal involvement in
these patients."
Sentinel lymph node biopsy has also
been modified for more common
tumors. In colon cancer, the procedure
is used solely for staging purposes, to
help the oncologists decide whether to
administer chemotherapy. Performing
a sentinel lymph node biopsy in place
of a complete lymph node dissection
in patients with colon cancer does
not reduce surgical morbidity because
there are no side effects associated with
removing the mesenteric lymphatics.
Thus, lymphatic mapping is sometimes
performed ex vivo when there is too
much fatty tissue inside the body to see
the nodes. In ex vivo mapping, the
surgeons inject the localization agents,
resect the tumor and the lymphatics,
and then remove any positive nodes for
analysis. While the false-negative rates
of sentinel lymph node biopsy are
higher in colon cancer than in melanoma or breast cancer, there is hope
that the rates will improve with the
development of more sensitive pathologic techniques.
As more patients enroll in clinical
trials of these experimental sentinel
lymph node biopsies, surgical oncologists
will continue to perfect the procedure so
that staging and even survival benefits
may be realized for patients with many
different kinds of tumors. •
FOR MORE INFORMATION) contact Dr.
Esmaeli at (713) 794-124 7 or Dr. Ross
at (713) 792-7217.
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Sentinel Lymph Node Biopsy
(Continued from page 3)
look, the more you find. Sometimes
we're actually finding just single cells
that look like they're probably malignant cells," said Dr. Hunt. "The question is, are those cells just passing
through the lymphatic system and
would normally be cleared out by the
lymphatics, or are they truly an important biologic event that we then need
to treat with more surgery or chemotherapy?"
One of the biggest controversies in
sentinel lymph node biopsy is whether
surgeons should remove all of the nodes
when micrometastatic disease is found.
To answer this question, researchers
are developing prediction models. In a
study of 160 patients with breast cancer
who had positive sentinel nodes, Dr.
Hunt and others found that using
additional parameters-such as the
size of the metastasis in the lymph
node, the presence or absence of
lymphovascular invasion in the primary
tumor, the number of lymph nodes that
were removed, and the size of the
primary tumor-they could predict
which patients were going to have
additional nodal metastases and
which were not.
"I think the challenge for sentinel
lymph node biopsy is to continue to
refine the groups of patients who will
most benefit from the technique," said
Dr. Lee. "Most important, it will be
helpful to identify patients who may
not need completion lymph node
dissection."

No two lymphatic systems are
exactly the same, so it is not always
possible to predict clinically or anatomically where a tumor will drain. Furthermore, certain areas of the body, such as
the head, neck, and trunk, have ambiguous drainage patterns. In the trunk,
for example, about 5% to 10% of tumors
migrate to ectopic or interval node
groups in addition to the usual inguinal
and axillary nodes, said Dr. Ross.
In breast cancers, while most tumors
drain to the axilla, there are some that
drain to the internal mammary nodes,
the supraclavicular nodes, and the
intramammary nodes. Even using
4
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Dr. Robert Andtbacka
(left) , a fellow in the Department of Surgical Oncology,
and Dr. Merrick Ross , a
professor in the department ,
discuss a lymphoscintigram.

At right, the arrow indicates
a concentration of blue dye in
an axillary lymph node. The
gamma probe, bottom, is
inserted into the incision to help
the surgeons more precisely
locate the target node or nodes .
sentinel lymph node biopsy, surgeons
sometimes overlook or ignore these
unexpected nodal basins. "What we're
<loin with sentinel node ma in is
trying to be very focused. We're trying
to be more accurate with our staging
system. So why would we want to
ignore potential alternative drainage
sites?" asked Dr. Hunt.
Drs. Hunt and Delpassand have
found that the site of the tracer injection influences where it will drain.
Injections to the skin almost never
drain to the internal mammary nodes,
but injections to the breast parenchyma
drain to the internal mammary nodes in
about 15% to 20% of patients.
Preoperative chemotherapy for breast
cancer can potentially obfuscate drainage
patterns because the chemotherapy often

shrinks tumors, leaving scar tissue and
fibrosis th at make it hard for surgeons to
inject a tracer or dye into the tumor. In
melanomas, wide local excisions of the
trunk, which has an ambiguous drainage
pattern to begin with, can throw the
drainage off its normal path.
Surgical oncologists at M. D. Anderson see these and other challenges as
part of a learning curve to be overcome
with practice and knowledge. "I think
this is just an amazing opportunity to ...
look at the anatomy and the drainage
of each individual tumor very carefully,"
said Dr. Hunt. •
FoR MORE INFORMATION, contact Dr. Lee
at (713) 792-7218, Dr. Delpassand at
(713) 792-7031, Dr. Ross at (713) 7927217 , or Dr. Hunt at (713) 792-7216 .

New Research Promotes a More Dynamic
View of Adult Stem Cell Differentiation
Hematopoietic Stem Cells May One Day Be Used to Repair
Tissue Damage Caused by Radiation Therapy or Chemotherapy
by David Galloway

he classical model
of the human cell
system has cells
traveling on a one-way street: An embryo is con-ceived, and embryonic stem cells
grow into adult cells that form
specific parts of the body, carry
out their functions, and then
die. Once a cell becomes a liver
cell, for example, it remains a
liver cell for the rest of its life.
But recent research suggests
a more dynamic picture , with
cells constantly dying and being
replaced by newly created cells
of uncertain origin. It might
even be possible for a liver
cell to generate brain cells.

Embryonic and Adult Stem Cell Differentiation

T

"When I grew up, I was taught
that neuronal cells were irreplaceableif you lose them, you've lost them for
life," said Zeev Estrov, M.D., a professor
in the Department of Bioimmunotherapy at The University of Texas
M. D. Anderson Cancer Center. That
belief is being challenged as researchers
begin to unravel the mysteries of adult
stem cells.
"It's so fascinating, if you really think
it through- and this is all hypothetical-that our cell system and our body
are much more dynamic than what we
had thought," said Martin Korbling,
M.D., a professor in the Department
of Blood and Marrow Transplantation
at M. D. Anderson.
In this dynamic model, the body is
constantly repairing itself. For example,
Dr. Estrov said, "If you walk outside
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Embryonic stem cells are capable of differentiating into any of the three germ-layer cells .
Adult stem cells were believed to differentiate only along a certain pathway , but some
recent studies have suggested that hematopoietic stem cells can cross germ-layer boundaries to form endodermal or ectodermal cells.
today, and you stay out a little bit
longer, then you can't even describe
what happens in your lungs. You inhale
all the smoke and dust and toxins, and
the body deals with it very successfully.
When there is a fai lure in the system,
you'll be short of breath. It happens
because the system has failed. But
usually, for most people, the system is
successful. There is damage and repair."
Most of this cycle of damage and
repair occurs within individual cells.
In some cases, however, large numbers
of specific cells may be needed to repair
tissues. Scientists have known for some
time that certain adult stem cells, the
hematopoietic progenitor cells, create
red blood cells. Drs. Estrov and Korbling
have researched using such cells to
direct the repair of tissue damage.
In a study published in 2002 in the

New England Journal of Medicine, they
found that circulating stem cells could,
as expected, differentiate into mature
blood cells, but they could also become
hepatocytes and epithelial cells of the
skin and gastrointestinal tract.
Other studies have shown potential
benefits of adult stem cell treatment in
repairing heart muscle damage due to
infarction, in regenerating blood vessels
to reverse ischemia in lower extremities,
and even in repairing spinal cord injuries.
Clinical studies are under way to investigate potential treatment strategies,
including the repair of tissue damage
caused by chemotherapy or radiation
therapy by increasing the concentration
of stem cells at the site of damage. This
can be done either by injecting stem
cells directly into the area where they
(Continued on page 6)
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Research Promotes a More Dynamic View of Adult Stem Cells
(Continued from page 5)

are needed or by administering human
granulocyte colony,stimulating factor
systemically.
The mechanism of adult stem cell
differentiation are not c mpletely
understood, but possible explanation
for the differentiation of adult tern cells
derived from bone marrow or corporeal
blood into non,lymphohematopoietic
tissue cells include the following:
• In the determini tic model, everal
types of stem cells circulate, and
each distinct type differentiates into
a pecific kind of ti ue.
• In the somatic stem cell model,
multipotent adult progenitor cells,
primordial equivalent of embryonic
tern cell , give rise to circulating,
lineage,restricted stem cell .

" .. .when you understand the me hanisms by
which a cell from one ti ue can be repro ..
grammed to become a cell of another ti ue,
then, in theory, you can take a an er ell
and reprogram it to be non an erous."
- Zeev Estrov, M.D.,
professor, Department of
Bioimmunotherapy

"It's so fascinating ... that our cell sy tem
and our body are much more dynamic
than what we had thought."
- Martin Korbling, M.D., professor,
Department of Blood and Marrow Transplantation

to the ame level found in the re t f
the patient' bone .
Both Dr. E trov and Dr. Korbling
said they were in pired by the work f
• In the tran differentiation model,
Helen M. Blau, Ph.D., a profe r in
a stem cell that normally fo llow
the Department of Microbiology and
a certain differentiation pathway
Immunology at the Stanford Univer ity
deviates and cro e over to a
School of Medicine. In the Jun 29,
different lineage.
2001, i ue of Cell, Dr. Blau' article
titled "The Evolving Concept of a t m
• In the dedifferentiation and rediffer,
Cell: Entity or Function?" put fi rth th
entiation model, a differentiated cell
hypothe i that a tern cell i d fined
regain tern cell-like propertie and
le by what it i than by what it d
generate differentiated cell of
" o [Dr. Blau' argument i that] any c 11
another tis ue .
can acquire the tern cell functi n und
certain condition ," Dr. Korbling aid.
Although none of the e model ha
"Your kin cell can acquire th t m
been proven, preclinical data upport
cell function and go back and pr due
_ __j__,t._h"'e'
._ ----'t'-ra
'--'.._.n'""""d'-iffi
'--''"'--'e"""r_,. e_.__.nc<,__!ti,_.,._a_., __.ti"o.....,n_._
"' m
_.__.,_,_. ._,e, ,__.l-'. .----.._.
I _..·"'---"'-,,,,,,_,_ __..,_,_,. .m
_._.__,,._,. . . . . ._.·e else It's a very, very dynamic
pos ible, however, that more than one
under randing of the univer e of tern
model may be at work imultaneou ly.
cell biology."
Mo t adult hematopoietic tern
One benefit for re earcher u ing
cells reside in the bone marrow. Only
adult stem cell rather than embryonic
about 0.1% of the body' stem cells are
stem cells i the avoidance of contra,
circulating in the corporeal blood at
versy. The political, ethical, and
any given time. These cells circulate
religious objections to embryonic rem
to create homeostasis, ensuring that
cell research do not apply to the field
the percentage of stem cells in the
of adult stem cells. According to Dr.
marrow remain uniform among the
Korbling, however, adult stem cell
more than 200 bones in the human
research cannot obviate the need for
body. For example, if the bone marrow
embryonic stem cell research. "An
in a patient's leg is destroyed by radia,
embryonic stem cell can differentiate
tion therapy, tern cells circulating in
into all three germ layers-me oderm,
the corporeal blood will be delivered
ectoderm, and endoderm," Dr. Korbling
to the ire of damage until the tern cell
aid. "This is the most totipotency you
concentration in tho e bones increase
can imagine, but it is lo t almo t
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which a cell
from one ti u can be reprogrammed to
become a cell fan ther ti ue, then in
theory, ou can take a cancer cell and
reprogram it to be noncancerou ,' Dr.
Estro aid. " o it like e ery other field
of medicine: You tart from one field,
and then ou ha e implication for
many, man ther field . It' ne er
limited." •
foR MORE INFORMATION , contact Dr.
Estrov at (713) 794, 1675 or Dr. Korbling
at (713) 745, 3219 .

PHYSICIANS:

THIS PAT IENT INFORMATION SHEET IS YOURS TO COPY

AND PASS ON TO PATIENTS.

Understanding the
Buzz over Stem Cells
human stem cell is very much like a queen bee's egg.
A beehive must have the right numbers of the right types
of bees to survive and produce honey. Although the
queen's eggs are all exactly alike, the worker bees treat
the honey with special ingredients to control what types of bees
develop: workers, drones, guards, or another queen. Therefore,
each egg has the potential to become any type of bee in the hive.
This same potential exists in stem cells.
Embryonic Stem Cells

Adult Stem Cells

stem cells have the
potential to specialize.
from stem cells donated for bone
marrow transplants became functioning
liver cells. Further testing revealed
donor-derived stem cells in the liver,
skin, and gut tissue of transplant
recipients. This discovery means that
stem cells circulating in the blood might
be used in treatments to repair many
different kinds of tissues or organs.
The potential of stem cell research
is as unlimited as that of the stem cells
themselves. Knowing the difference
between embryonic and adult stem cells,
their origins, and their potential uses in
medicine will help guide decisions about
their research and development. •

Embryonic stem cells can become
Fortunately, this moral dilemma
any of the more than 200 cell types in
does not exist with the use of adult
the human body. This unique characterstem cells. Unlike embryonic stem
istic gives them tremendous potential as
cells, adult stem cells are scattered
a treatment for many different diseases
throughout the tissues of the body,
and conditions, which is why they are
and they are far more difficult to isolate
the most interesting stem cells to
and grow in culture than are embryonic
scientists.
stem cells. However, much like embryEmbryonic stem cells h ave not yet
onic stem cells, adult stem cells are
been used to treat humans, but scientists unspecialized cells that can generate
hope to eventually use them to develop
specialized cells, such as nerve cells,
replacement cells and tissues for parts
bone cells, liver cells, and muscle cells.
of the body that are damaged, diseased,
Adult stem cells can proliferate, or
or worn out. Once scientists discover
replicate themselves, for years and
how to control the types of cells that
continue to produce differentiated,
embryonic stem cells become and
or specialized, cells as needed. When
overcome other obstacles, they will
tissue is damaged, adult stem cells
be able to transplant specialized cells
produce cells to replace the damaged
derived from embryonic stem cells into
ones. Adult stem cells generally produce
patients to treat many conditions, such
the cell types of the tissue in which they
as Parkinson's disease, diabetes, spinal
live. Until recently, they were thought
cord injury, and heart failure.
to be able to produce only those cell
The use of human embryonic stem
types, but new evidence shows that at
- - cellsfor researcnanchh.erapy-i:s-contro-- - least- semg_adulLStem_c.dls can 12roduce
versial, however. Embryonic stem cells
the cells of oth er tissues. For exa::m:-:p:"il-::
e,- -1,
used for research typically come from
adult bone marrow or peripheral bloodfour- to five-day-old embryos, whose
derived stem cells can produce heart,
development must be terminated to
skeletal muscle, skin, brain, and
extract the stem cells (30-40 cells). The
lung cells.
embryos come from in vitro fertilization
Stem cells found in bone marrow
clinics, where the eggs of women who
have been transplanted from healthy
are having difficulty becoming pregnant donors to sick patients for more than
are fertilized in a laboratory. Not all of
40 years to treat many blood disorders
the fertilized eggs from each woman
and leukemia and lymphoma. In studies
who is treated at the clinic are imof a very limited number of patients,
planted into the woman 's womb, and
adult stem cells have even been used
some of the "extra" embryos are used in
to treat patients with diabetes or
stem cell research. The point is that
advanced kidney cancer. Recently,
each healthy embryo h as the potential
researchers at M. D. Anderson Cancer
to become a baby.
Center discovered that cells derived

More information about stem cells
and stem cell research can be found
at the following National Institutes of
Health Web sites:
• http://stemcells. nih.gov/
infoCenter/stemCellBasics.asp
and
• http://www.nih.gov/news/
- ~
s t=e=m:-::c~eTlllT
/.- ---='---___:___ ___:____ _ _-l--_l--

For more information, contact
your physician or contact the
M . D . Anderson Information Line:
({) (800) 392-1611 within
the United States, or
({) (713) 792-6161 in Houston
and outside the United States .
September 2003
©2003 The University of Texas
M. D. Anderson Cancer Center
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Directed Parathyroid Surgery
Jeffrey E. Lee, M.D.
Professor, Department of
Surgical Oncology
Directed operations
such as sentinel
lymph node mapping can potentially
improve the effecti vene s of taging
and therapy and at
the same time
minimize morbidity.
Similarly, patient
with primary hyperparathyroidi m can
undergo a directed operation with high
ucce and low morbidity when a combination of preoperative e tamibi imaging and
the rapid intraoperative as ay for parathyroid hormone (rPTH) i u ed. Thi approach ha become an important component of a minimally inva ive parathyroidectomy that utilize mall inci ion and local
ane the ia and ha been applied to the
treatment of patients undergoing initial
and reoperative parathyroid urgery.
Technetium (Tc)-99m e tamibi imaging
has become a tandard part of the preoperative evaluation of patients with hyperparathyroidism. In approximately 80% of patients, the technique uccessfully localizes a
parathyroid adenoma, which allows for a
directed operation. In the 20% of patients
in whom localization is unsuccessful, a repeat
study following short-term thyroid uppre sion with liothyronine is safe and can result
in successful localization.
At M. D. Anderson Cancer Center,
we employ an rPTH a ay that delivers
re ults within 15 minutes of pecimen
collection. Ba eline amples are compared
8
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with ample tak n fiv and 10 minut
po texci i n. A 50% drop in th rPTH
value from ba elin i indicativ f clinic
cure in patients with primary hyp rp rathyroidi m. A le er drop in the rPTH
level call for bilateral neck xpl rati n t
determine the pre ence r ab nc f
multigland di ea . In pati nt with
multiple end crine n opla ia typ 1, wh
typically have multigland di a and ar
at ri k for recurrent hyperparathyr idi m,
it i rea onable to target an 0% fall in
the rPTH value; thi rate al w rk
well for patient with ec ndary hyp rparathyroidi m or parathyroid hyp rpla ia.
In the e patient , it i al d irabl t
have the rPTH level fall to within th
normal range.
While not ential to the routin mana
ment of patients with primary hyperparathyroidi m, intraoperative gamma probe localization can be us d. The gamma probe may
be particularly helpful during re perati
urgical procedure .
We ha~e found that preoperati e
sestamibi cintigraphy, combined with the
rPTH as ay, allow for a ucce ful directed
parathyroidectomy in mo t patient and
that this minimally inva ive approach i
well tolerated. Patients appreciate thi
approach becau e, mo t of the time, it
allows them to avoid the ide effects of
general anesthesia. Their reco ery i fa ter
and more comfortable, and urgery can
usually be performed a an outpatient
procedure. A an endocrine urgeon, I find
it ati fying to be able to perform a directed
operation and be confident before lea ing
the operating room that the patient'
hyperparathyroidi m ha been cured.
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